Related Experiment Video
Updated: May 12, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Early-stage thymic carcinoma: is adjuvant therapy required?
Mitsuaki Sakai1, Takuya Onuki, Masaharu Inagaki
1Department of Thoracic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;
Journal of Thoracic Disease
|April 16, 2013
Summary
For early-stage thymic carcinoma, surgery alone may be sufficient. This study found that radical resection without adjuvant therapy resulted in no recurrence in Masaoka stage II patients.
Area of Science:
- Oncology
- Thoracic Surgery
- Cancer Research
Background:
- Advanced thymic carcinoma generally has a poor prognosis.
- Adjuvant therapy following surgery for Masaoka stages I/II thymic carcinoma is debated.
- Previous studies suggest high survival rates with surgery plus adjuvant therapy for early stages.
Purpose of the Study:
- To evaluate the outcomes of Masaoka stage II thymic carcinoma treated with surgery alone.
- To determine if adjuvant therapy is necessary for early-stage thymic carcinoma.
Main Methods:
- Retrospective analysis of 4 patients with Masaoka stage II thymic carcinoma.
- All patients underwent transsternal thymectomy without lymph node dissection or adjuvant therapy.
- Tumor evaluation via chest X-ray and CT; needle biopsy was not performed.
Main Results:
- All 4 patients with Masaoka stage II thymic carcinoma survived and remained relapse-free at a median follow-up of 72 months.
- Histopathology revealed squamous cell carcinoma (3) and undifferentiated carcinoma (1).
- No evidence of adjacent organ invasion or lymph node metastasis was found.
Conclusions:
- Radical resection without adjuvant therapy may be a viable treatment option for early Masaoka stage thymic carcinoma with low-grade histology.
- This approach could potentially avoid the morbidity associated with adjuvant treatments.
- Further research with larger cohorts is warranted to confirm these findings.
